ENHANZE royalties jumped 44% to a record $341 million, and management raised full-year non-GAAP EPS guidance to $8.75-$9.05. The royalty engine is now carrying the story, even as shares slipped in the minutes after the release.
Latest Activity
HALO Coverage
Buy, Sell, or Hold? Wednesday’s Top Upgrades and Downgrades: Akamai Technologies, Apple, BILL Holdings, Corning, Form Factor, Guidewire Software, NVIDIA, Riot Platforms, Toast, and More
Pre-Market Stock Futures: Futures are trading higher after a wild Tuesday, when we warned everybody to get their popcorn ready because the inflation news could cause some fireworks, and sure enough, it…
Analysts Just Upgraded these Five Stocks
Live Updates No updates were posted during this live coverage. Here are a few recent upgrades you may want to pay attention to. Palantir Technologies Palantir Technologies (NYSE: PLTR | PLTR Price…
Add These 5 Hot Biotech Stocks In July
Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you’re investing…
Thursday’s Top Analyst Upgrades and Downgrades: Airbnb, Antero Midstream, Exact Sciences, GitLab, Lumentum, Nektar Therapeutics, PayPal and More
Thursday's top analyst upgrades and downgrades included Airbnb, Alcon, Antero Midstream, Exact Sciences, GitLab, GlobalFoundries, Halozyme Therapeutics, Lumentum, Nektar Therapeutics, PayPal and Southern Copper.
Monday’s Analyst Upgrades and Downgrades: Chipotle, CRISPR, Hess Midstream, iMedia, Kinder Morgan, Wendy’s and More
Monday’s top analyst upgrades and downgrades included Chipotle Mexican Grill, CRISPR, Hess Midstream, iMedia Brands, Kinder Morgan, Wendy’s and more.
Monday’s Top Analyst Upgrades and Downgrades: Foot Locker, Halozyme Therapeutics, Kimberly-Clark, Occidental Petroleum, Texas Roadhouse, Trip.com and more
Monday's top analyst upgrades and downgrades included Foot Locker, Halozyme Therapeutics, Kimberley-Clark, Occidental Petroleum, Texas Roadhouse, Trip.com and Williams Companies.
Top Analyst Upgrades and Downgrades: Alphabet, Chevron, Citigroup, Facebook, Fastly, Paypal, Snap, Twitter, Under Armour and More
Thursday's top analyst upgrades and downgrades included Alphabet, Chevron, Citigroup, Facebook, Fastly, Paypal, Snap, Twitter and Under Armour.
Top Analyst Upgrades and Downgrades: Aetna, Analog Devices, Lowe’s, Merck, Pfizer, Plug Power, Qualcomm, Target and More
The top analyst upgrades, downgrades and initiations seen on Thursday include Aetna, Analog Devices, Lowe's, Merck, Pfizer, Plug Power, Qualcomm and Target.
50 Mid-Cap and Larger Stocks More Than Doubled in 2017
With 2017 nearing an end, it is important to consider just what has happened. 24/7 Wall St. has screened 50 stocks that have risen 100% or more (some far more) in 2017.
Halozyme Therapeutics Wins Big on Roche License Agreement
Halozyme Therapeutics saw its shares make a handy gain early on Thursday after the firm announced that it licensed its Enhanze drug-delivery technology to Roche for exclusive development of an “undisclosed therapeutic…
Why These 5 Biopharma Stocks Are Making Massive Gains on Thursday
As the markets are continuing to heat up, a few biopharma stocks made massive gains on Thursday. There is a very positive sentiment in the health care sector in anticipation of the…
3 Top Biopharma Movers of the Past Week
Over the past week, Halozyme Therapeutics and a couple of other biotech companies made impressive runs.
4 Top BioPharma Movers of the Past Week
These biotech companies stood out from the rest with big moves over the course of the past week.
Halozyme Therapeutics Sinks on Business Update
Halozyme Therapeutics hit a new 52-week low in Monday's session following the release of a business update at JPMorgan’s 34th Annual Healthcare Conference.
How Halozyme Will Continue to Grow With Its New Deal
Halozyme Therapeutics has announced a global collaboration and license agreement with AbbVie.